Free tool
FAERS Monitor: Katerzia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211340 or its brand name (Katerzia, Amlodipine Benzoate). Reports on generic versions are filed under their own applications.
Reports
272,620
Serious
210,866
77% of reports
Hospitalization
109,379
Death reported
29,868
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue16,575
- diarrhoea14,880
- nausea14,108
- dyspnoea13,790
- drug ineffective12,841
- off label use12,062
- dizziness11,278
- headache10,422
- acute kidney injury9,953
- pain9,610
- vomiting9,272
- fall8,925
- asthenia8,849
- hypotension8,776
- malaise8,330
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 744 |
| 2005 | 878 |
| 2006 | 1,036 |
| 2007 | 1,407 |
| 2008 | 1,912 |
| 2009 | 3,213 |
| 2010 | 4,129 |
| 2011 | 5,415 |
| 2012 | 7,098 |
| 2013 | 7,601 |
| 2014 | 10,322 |
| 2015 | 14,615 |
| 2016 | 16,314 |
| 2017 | 18,466 |
| 2018 | 22,937 |
| 2019 | 24,686 |
| 2020 | 23,029 |
| 2021 | 20,669 |
| 2022 | 18,630 |
| 2023 | 19,083 |
| 2024 | 17,923 |
| 2025 | 18,338 |
| 2026 | 14,174 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,781,539 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 9,953 | 5.3 | 5.2 | 32,673 |
| hypotensionSignal | 8,776 | 3.5 | 3.4 | 15,003 |
| fallSignal | 8,925 | 2.1 | 2.1 | 5,073 |
| dyspnoea | 13,790 | 1.9 | 1.9 | 5,907 |
| asthenia | 8,849 | 1.8 | 1.8 | 3,344 |
| diarrhoea | 14,880 | 1.8 | 1.8 | 5,299 |
| dizziness | 11,278 | 1.8 | 1.7 | 3,718 |
| fatigue | 16,575 | 1.7 | 1.6 | 4,382 |
| vomiting | 9,272 | 1.5 | 1.5 | 1,717 |
| malaise | 8,330 | 1.5 | 1.4 | 1,273 |
| nausea | 14,108 | 1.4 | 1.4 | 1,520 |
| headache | 10,422 | 1.3 | 1.3 | 677 |
| pain | 9,610 | 1.2 | 1.2 | 356 |
| off label use | 12,062 | 1.1 | 1.0 | 47 |
| drug ineffective | 12,841 | 0.7 | 0.7 | 1,138 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.